Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
No, Trump did not get rid of Medicare’s $35 insulin cap
Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly ...
RFK Jr.’s plan for pharma ads would run straight into the First Amendment
Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Hims & Hers to Advertise Weight-Loss Shots at the Super Bowl
Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...
Jim Cramer on Eli Lilly and Company (LLY): ‘It’s About The Scripts, Not About The Pill’
We recently compiled a list of the Jim Cramer Discussed These 11 Stocks Before The DeepSeek Sell-Off. In this article, we are ...
Business Insider5d
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...
FiercePharma4d
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief
Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound ... market launch with a new commercial leader.
Yahoo Finance1d
Eli Lilly and Company (LLY)
In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an ...
The Motley Fool6d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
Business Insider3d
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...
Business Insider4d
Eli Lilly & Co (LLY) Gets a Buy from Citi
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...